Stay updated on Long-term Safety of Dupilumab in Pediatric AD Clinical Trial
Sign up to get notified when there's something new on the Long-term Safety of Dupilumab in Pediatric AD Clinical Trial page.

Latest updates to the Long-term Safety of Dupilumab in Pediatric AD Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedRevision updated from v3.4.2 to v3.5.0.SummaryDifference0.0%

- Check44 days agoChange Detected- Revision label updated from v3.4.1 to v3.4.2. No substantive content changes to the page.SummaryDifference0.0%

- Check51 days agoChange DetectedThe page shows a revision update from v3.4.0 to v3.4.1 with no visible changes to core content or study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check58 days agoChange DetectedShow glossary added; minor capitalization changes to QC-related labels; and the revision number updated from v3.3.4 to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check73 days agoChange DetectedRevision: v3.3.4 was introduced, replacing the previous v3.3.3; this appears to be a minor site version update with no changes to the study details, locations, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check94 days agoChange DetectedLocations section expanded with new site locations across the United States, Canada, and Europe. The HHS Vulnerability Disclosure entry was removed.SummaryDifference2%

Stay in the know with updates to Long-term Safety of Dupilumab in Pediatric AD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Long-term Safety of Dupilumab in Pediatric AD Clinical Trial page.